CRISPR Therapeutics' CEO said he hoped to have a product on the market in the next four or five years. Read more at ...
Adding Amgen's AMGN.O cholesterol drug Repatha to standard therapy reduced major cardiovascular events by 25% for at-risk patients who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback